NOTE TO READERS: When this project lost substantial funding at the end of 2018, I lost the ability to continue publishing criteria-driven news story reviews and PR news release reviews - once the bread-and-butter of the site going back to 2006. The 3,200 archived reviews, while still educational, are getting old and difficult for me to technically maintain on the back end of the website. So I am announcing that I plan to remove these reviews from the site by April 1, 2021. The blog and the toolkit - two of the most popular features on the site - will remain. If you wish to peruse the reviews before they disappear, please do so by the end of March 2021. After that date you may still be able to access them via the Internet Archive Wayback Machine -

Hope? Perhaps. But tough questions not asked/answered by CNN on islet cell transplants

One of our readers who has Type I diabetes wrote to me about a story on last week – about islet cell transplantation offering “hope for Type 1 diabetes.”

Indeed, such transplants do offer some hope to some people.

But our interested reader asked why there was no discussion of:

  • cost?
  • side effects of immunosuppressant therapy?
  • alternatives?
  • history of failures of islet transplants?
  • measurable impact of the treatment (hemoglobin A1c improvement?)
  • why would insurance pay for an experimental therapy?

Indeed, CNN devoted more than 1,300 words to this online story, but none to the important questions our reader raised.

But an editor’s note at the top of the piece announces that November is National Diabetes Month – so maybe the intent is to promote progress and not ask evidence-based questions.


Follow us on Twitter:

and on Facebook.


You might also like


Please note, comments are no longer published through this website. All previously made comments are still archived and available for viewing through select posts.

Comments are closed.